peptides for FAQ

Continue the protocol through week 8–10 before concluding non-response. BPC-157's mechanism involves phenotypic changes in mast cells and reduction of pro-inflammatory mediator production. These are gradual biological shifts, not receptor blockade that produces immediate effects. Studies showing reduced substance P and neuropathic pain scores measured outcomes at 6–8 weeks, not 2–4 weeks. If no improvement appears by week 10, reassess dosing (some protocols use 500–750 mcg daily for severe presentations) or consider combination with thymosin beta-4 to address both peripheral mast cell and central microglial components simultaneously.

Selank and Semax have no documented cytochrome P450 interactions, but their GABAergic and neurotrophic effects may potentiate benzodiazepines, SSRIs, or other psychoactive medications. If currently on anxiolytics or antidepressants, monitor for excessive sedation or mood changes when adding Selank. Thymalin's immune-modulating effects could theoretically interfere with immunosuppressants. Consult the prescribing physician before combining thymosin peptides with corticosteroids, TNF-alpha inhibitors, or other immune-targeted therapies.

Temperature-sensitive peptides degrade irreversibly when exposed to heat. If lyophilised peptides arrive above room temperature (25°C+) for more than 24 hours, molecular structure may be compromised. Visual inspection is useless. Degraded peptides look identical to intact ones. Request replacement if cold-chain integrity is questionable. Once reconstituted, refrigerate immediately and never allow the solution to reach room temperature for more than 30 minutes during dosing. Purpose-built peptide coolers maintain 2–8°C for 36–48 hours without electricity, essential for travel.

No. Never double-dose peptides. Thymalin's immune-modulating effect is cumulative but dose-sensitive; administering 20mg instead of 10mg doesn't accelerate Treg recovery. It oversaturates receptors and triggers downregulation, reducing subsequent doses' efficacy. If you miss a twice-weekly dose by fewer than 48 hours, administer it as soon as remembered and continue the regular schedule. If more than 48 hours have passed, skip the missed dose entirely and resume on the next scheduled date. Consistency matters more than total weekly dose.

Starting neuroprotective peptides before symptoms emerge is the theoretical optimal window, but no clinical trial has validated this approach. APOE ε4 carriers have 3–12 times higher Alzheimer's risk depending on whether they carry one or two copies of the variant, and synaptic loss begins 10–15 years before cognitive decline is detectable. Hypothetically, peptides like Cerebrolysin or P21 administered intermittently (quarterly cycles rather than continuous use) could maintain baseline synaptic density during this presymptomatic accumulation phase. The counterargument: without human prevention trial data, you're using compounds validated only for symptomatic treatment in a fundamentally different biological context.

This reflects immune reconstitution inflammatory syndrome (IRIS). A transient worsening of symptoms as the immune system reactivates and clears latent viral reservoirs or damaged cells. It occurs in 15–25% of patients starting thymic peptides and typically resolves within 7–10 days. Reduce the next Thymalin dose by 50% (5mg instead of 10mg) and extend the interval between injections to every other day instead of daily. Once symptoms stabilise, resume standard dosing.

This is mechanistically sound. Thymalin targets immune function while epithalon acts on circadian and telomere pathways, with no receptor overlap. Russian gerontology protocols have used concurrent dosing (thymalin 10mg + epithalon 10mg daily for 10 days) without reported interference. The constraint is injection site management and cost, not biological conflict. If running both, maintain the same washout intervals (90 days minimum) for each peptide independently.

Yes. Thymic peptides like Thymalin operate through immune modulation pathways entirely separate from thyroid hormone replacement, so there's no pharmacological interaction or contraindication. Levothyroxine replaces deficient T4; Thymalin reduces the autoimmune attack causing that deficiency in the first place. Research from the International Journal of Immunopharmacology documented that participants on stable levothyroxine doses who added Thymalin 10mg twice weekly showed reduced anti-TPO antibodies without requiring levothyroxine dose adjustments. The peptide doesn't alter thyroid hormone metabolism or clearance rates.

No. Thymalin and immunosuppressants work through opposing mechanisms. Thymalin activates T-cell proliferation; drugs like methotrexate, azathioprine, or corticosteroids suppress it. The interaction isn't just ineffective. It's counterproductive. If you're tapering off immunosuppressants under medical supervision, wait until you've been off the medication for at least 4 weeks (one full T-cell turnover cycle) before starting Thymalin. This washout period ensures the thymus isn't receiving simultaneous activation and suppression signals.

This means one of three things: the peptide isn't engaging the relevant receptors, the dose is below the therapeutic threshold, or the primary pathology isn't the mechanism the peptide targets. Cerebrolysin non-responders often have minimal baseline synaptic loss. The compound supports existing neurons, not generalised cognitive enhancement. Consider switching to a different mechanism (anti-inflammatory vs synaptogenic) or increasing cumulative dose. Protocols below 300ml total Cerebrolysin rarely show clinical benefit.

HCG alone preserves fertility in 50–65% of men on TRT, which is better than the 8% success rate with testosterone monotherapy. Adding recombinant FSH (not a peptide, but mechanistically necessary for spermatogenesis) increases that figure to 75–80%. The protocol: HCG 250 IU every other day + FSH 75 IU three times weekly. Monitor semen analysis every 12 weeks. If sperm count remains above 5 million/mL, the protocol is working. If counts drop below 1 million/mL after six months, consider stopping testosterone entirely and switching to enclomiphene monotherapy (12.5–25mg daily), which maintains testosterone while preserving endogenous production.

Cortisol modulation is necessary but not sufficient for resolving chronic stress symptomatology. If salivary cortisol normalizes but fatigue, sleep disruption, or cognitive symptoms persist, the issue may be downstream. Mitochondrial dysfunction, neurotransmitter depletion, or tissue-level insulin resistance. Peptides like Cerebrolysin address neuroplasticity pathways separately from HPA modulation.

Stop at 20 days maximum. Extending epithalon beyond this window doesn't increase telomere lengthening or melatonin production. It accelerates pineal receptor desensitisation, reducing the protocol's effectiveness in subsequent cycles. The 10–20 day window matches the timeline for maximal gene expression changes in pineal tissue, after which the response plateaus. If you've already run a longer cycle, wait 90 days before the next one to allow receptor density to recover.

Cholinesterase inhibitors (donepezil, rivastigmine) and neuroprotective peptides target different mechanisms. The former prevents acetylcholine breakdown to temporarily boost neurotransmission, while peptides like Cerebrolysin promote structural synaptic repair. No drug-drug interaction studies exist, but the mechanisms are complementary rather than overlapping. Cerebrolysin trials included patients on background cholinesterase inhibitor therapy without adverse interactions. The practical constraint: adding peptides requires medical oversight to monitor cumulative cognitive effects and rule out adverse events that neither therapy alone would cause.

Initial symptom exacerbation can occur if the peptide triggers transient immune activation before stabilization effects dominate. This is rare but documented in immune-modulating interventions. Reduce the dose by 50% for one week, then gradually titrate back up if symptoms normalize. If worsening persists beyond 7–10 days, discontinue and consult the prescribing clinician. Some patients experience injection site reactions (redness, mild swelling) that don't indicate systemic intolerance. Localized histamine release at the injection site is mechanistically distinct from systemic symptom worsening.

Without baseline measurement, you can't differentiate peptide effects from placebo, practice effects, or natural variation in cognitive performance. Establish a baseline using standardised tools. Montreal Cognitive Assessment (MoCA), Trail Making Test, or digit span tests. Before starting any intervention. Repeat testing at 8-week intervals to detect meaningful change. Subjective improvements ('I feel sharper') don't correlate reliably with objective performance gains. Cognitive assessment apps like Cambridge Brain Sciences provide repeatable, normed tests that track performance over time without requiring clinical administration.

Extend the protocol to eight weeks (20 sessions total) and verify NAD+ cofactor status. Mitochondrial biogenesis requires NAD+ as an electron carrier. Patients with depleted NAD+ pools (common in chronic illness) can't synthesize new mitochondria regardless of PGC-1α upregulation. Nicotinamide riboside (300mg daily) or NMN (500mg daily) supplementation addresses this substrate bottleneck. If no improvement occurs by session 20, mitochondrial dysfunction may not be the primary driver of cognitive symptoms.

Skip this step and you're flying blind. You'll never know whether subjective 'mental clarity' reflects real cognitive improvement or placebo response. Obtain a Montreal Cognitive Assessment (MoCA) score before initiating any protocol; it's a validated 10-minute test that quantifies attention, executive function, and memory. Repeat it at 4-week intervals. A 2-point improvement on MoCA is clinically meaningful; anything less suggests the protocol isn't producing measurable benefit and should be adjusted.

Verify disease duration and baseline glandular damage via thyroid ultrasound. Patients with chronic Hashimoto's exceeding 10 years or advanced heterogeneous fibrotic changes show blunted peptide responses regardless of dosing. The Sechenov trial data showed that 18% of participants had no measurable antibody reduction at 12 weeks, clustered heavily in the subgroup with disease onset more than 8 years prior. Non-responders may benefit from extending treatment to 20 weeks or adding selenium (200mcg daily), which independently reduces anti-TPO by 8–12% and may act synergistically with thymic peptides.

Skip motility-targeting peptides entirely. Ghrelin agonists and motilin receptor modulators address MMC failure, not bacterial load reduction. If antroduodenal manometry or wireless motility capsule testing confirms normal phase III contractions, the SIBO driver is elsewhere: bacterial composition, bile acid malabsorption, or immune activation. Redirect intervention toward barrier-strengthening peptides like KPV or antimicrobial protocols.